MedTrace Logo

Use of Exhaled Particles to Assess Lung Pharmacokinetics

NCT04914273 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-10-15

No results posted yet for this study

Summary

This research project in humans aims at increasing the general understanding of lung pharmakokinetic by sampling exhaled particles. The central hypothesis of this study is that pharmacokinetics of Salbutamol (model drug) can be monitored in exhaled particles.

Conditions

  • Healthy
  • Lung Pharmacokinetic

Interventions

DRUG

Inhalation Spray

400 mcg salbutamol administered per metered dose inhaler

DRUG

Tablet

8 mg salbutamol administered per tablet for ingestion

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Fraunhofer-Institute of Toxicology and Experimental Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-14
Primary Completion
2021-08-03
Completion
2021-08-03

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04914273 on ClinicalTrials.gov